Persistent Asset Partners’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
– Sell
-1,560
Closed -$8.67K – 277
2025
Q2
$8.67K Buy
1,560
+1,456
+1,400% +$16.3K 0.01% 171
2025
Q1
$36.7K Hold
104
– – 0.03% 138
2024
Q4
$73.4K Buy
+104
New +$1.83K 0.06% 108

Other funds holding NKTR

Persistent Asset Partners's NKTR Position: Q3 2026 in Review

Persistent Asset Partners reduced its Nektar Therapeutics (NKTR) stake by 59% in Q3 2026, selling an estimated $312K and leaving 3,040 shares worth $184K. The position accounts for 0.05% of the portfolio, ranked #215.

Persistent Asset Partners first reported a position in NKTR in Q4 2024 and has held it in 5 quarters since. The position peaked at $983K in Q3 2025. 243 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Persistent Asset Partners held 3,040 shares of Nektar Therapeutics worth $184K as of Q3 2026.
  • Persistent Asset Partners sold 4,441 Nektar Therapeutics shares in Q3 2026, an estimated $312K.
  • Nektar Therapeutics made up 0.05% of Persistent Asset Partners's portfolio in Q3 2026, its #215 holding.
  • Persistent Asset Partners first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Persistent Asset Partners's Nektar Therapeutics position peaked at $983K in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.